Search

Your search keyword '"Efstathiou, Jason A."' showing total 1,149 results

Search Constraints

Start Over You searched for: Author "Efstathiou, Jason A." Remove constraint Author: "Efstathiou, Jason A."
1,149 results on '"Efstathiou, Jason A."'

Search Results

202. IMPACT OF SYNCHRONOUS BLADDER CANCER ON RECURRENCE-FREE SURVIVAL AFTER SURGICAL TREATMENT FOR PRIMARY URETHRAL CANCER: RESULTS FROM THE INTERNATIONAL COLLABORATION ON PRIMARY URETHRAL CARCINOMA (ICPUC): MP13-03

204. INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy.

205. The impact of a positive family history on clinical and pathologic outcomes of active surveillance for prostate cancer.

206. EA8185: Phase II study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), ECOG-ACRIN/nrg collaboration.

207. INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients.

209. Resolution of a High Grade and Metastatic BK Polyomavirus-Associated Urothelial Cell Carcinoma Following Radical Allograft Nephroureterectomy and Immune Checkpoint Treatment: A Case Report

210. Contributors

211. Bladder Cancer

217. Quality Indicators for Bladder Cancer Services: A Collaborative Review

221. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer

222. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

223. Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.

224. INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer—SWOG/NRG1806.

228. 328. Kaposi Sarcoma in High Population ART Utilization Setting: An Observational Study in Botswana

233. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis

234. Transforming growth factor beta stimulation of colorectal cancer cell lines: type II receptor bypass and changes in adhesion molecule expression

235. Comorbidity, body mass index, and age and risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence

237. Immunotherapy and Radiation – A New Combined Treatment Approach for Bladder Cancer?

240. Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11]

241. Trimodality Therapy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.

242. Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer.

243. The current state of randomized clinical trial evidence for prostate brachytherapy

245. Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level

248. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer

249. Molecular Characterization of Neuroendocrine-like Bladder Cancer

Catalog

Books, media, physical & digital resources